Ascites A to Z

Ascites A to Z — Comprehensive Clinical Summary

Presenter: Dr. Ethan Weinberg, Assistant Professor of Clinical Medicine, University of Pennsylvania

Forum: NIS International Medical Education Session

1. Main Clinical Topics Discussed

• Epidemiology and natural history of ascites in cirrhosis
• Clinically significant portal hypertension (CSPH) and risk stratification
• Diagnosis of ascites (paracentesis, SAAG, total protein)
• Dietary sodium restriction in ascites management
• Pharmacologic prevention and treatment of ascites (diuretics, non-selective beta-blockers, disease-directed therapies)
• Refractory and recurrent ascites
• Spontaneous bacterial peritonitis (SBP)
• Hepatic hydrothorax and thoracentesis
• Hepatorenal syndrome (HRS) as the end-stage complication

2. Key Learning Points, Guidelines, and Recommendations

Risk Stratification & Prevention

• CSPH (hepatic venous pressure gradient ≥10 mmHg) is the critical threshold at which decompensating events, including ascites, begin to occur
• In the US, non-invasive surrogates are preferred over direct HVPG measurement:

- FibroScan >25 kPa → rules in CSPH

- FibroScan <15 kPa + platelet count >150 × 10⁹/L → rules out CSPH

• Treating the underlying etiology of liver disease (HCV, NAFLD, alcohol-associated liver disease) significantly reduces hepatic decompensation and mortality
• Naltrexone for alcohol use disorder (AUD) is now incorporated into hepatology practice for patients with dual diagnosis of ALD + AUD, demonstrating reductions in decompensation and short- and long-term mortality
• Non-selective beta-blockers (NSBBs) — preferably carvedilol (if blood pressure tolerates) or nadolol — are now standard practice for preventing ascites in compensated cirrhosis with CSPH

Diagnosis

• Ascites is caused by cirrhosis in ≥75% of cases
• SAAG ≥1.1 g/dL indicates portal hypertension-related ascites (cirrhosis, cardiac ascites)
• Total protein differentiates etiology in high-SAAG ascites:

- Protein >2.5 g/dL → cardiac ascites

- Protein <2.5 g/dL → cirrhotic ascites (though overlap exists)

• Peritoneal carcinomatosis typically produces low SAAG ascites

Dietary Sodium Restriction

• Target: ≤2,000 mg (2 g) sodium per day (~90 mmol/day)
• Practical patient education is essential — many patients who report compliance are not actually adherent:

- Advising patients to avoid adding table salt is insufficient

- Restaurant and delivery foods are consistently high in sodium

- Meal recall during clinic visits is a recommended strategy

• Lower sodium intake → less fluid accumulation; diuretic requirements are reduced

Pharmacologic Treatment

• Diuretics remain a cornerstone: furosemide and spironolactone in combination
• Management extends well beyond "give furosemide and spironolactone" — disease phase, refractoriness, and complications must guide individualized therapy

3. Specific Clinical Data and Study Results Cited